Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7
Links:
Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh…
https://acrabstracts.org/abstract/efficacy-and-safety-of-deucravacitinib-an-ora…
13-11-2022